04.16.24 -- Continuous Manufacturing: Many Want It, But Here's Why Few Have It

Before pursuing an outsourcing strategy, it is essential to define what processes will be kept in-house and where your CDMO partner will take the lead.

Specializing in oncology, anti-infective and complex formulations, the facility provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

The development of drug delivery devices that are innovative, intuitive, patient friendly, and patient safe must address certain areas of concern that are particular to both biologic and biosimilar therapies.

This panel session features a decade-long story of partnership in bringing two life-changing gene therapies to market successfully in 2022.

Outsourcing is now a true collaboration in which innovators and CDMOs co-create the future of medicine. Explore how the right CDMO can help sponsors unlock the full potential of their biotherapeutics.

Manufacturing complex and highly potent ADC treatments presents unique challenges. Get an insider look at how these treatments make it from development to commercialization.

Access a thorough investigation that delves into the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

An emerging biotech company sought help developing a formulation for a monoclonal antibody. Explore how MilliporeSigma delivered an optimized formulation within an aggressive timeline and budget.

While breakthroughs with mRNA vaccines have ignited renewed interest in nucleic acid medicines, the road to wide adoption will present many challenges. Learn more about the future of these therapeutics.